Bolt Biotherapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Bolt Biotherapeutics

08/05/2023 12:30

* Bolt Biotherapeutics Inc  BOLT.OQ   BOLT.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 10
(estimated). 
    * The Redwood City California-based  company is expected to
report
 a 60.7% increase in revenue to $1.306 million from $813
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Bolt
Biotherapeutics Inc
is for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $4.5​, above​ its last closing price
of $1.61. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.60      -0.53     Beat    11.4
 Sep. 30 2022  -0.56       -0.56      -0.58     Missed  -3
 Jun. 30 2022  -0.69       -0.68      -0.61     Beat    10​
 Mar. 31 2022  -0.72       -0.72      -0.64     Beat    10.8
 ​​Dec.        -1.43       -0.82      -0.73     Beat    10.8
 31 2021                                                
 Sep. 30 2021  -0.66       -0.65      -0.63     Beat    3.4​
 Jun. 30 2021  -0.43       -0.43      -0.64     Missed  -48.8
 Mar. 31 2021  -0.60       -0.60      -1.14     Missed  -90
 This summary was machine generated May 8 at 11:30 GMT.  All
figures in US dollars  unless otherwise stated